We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

46 hedge funds and large institutions have $109M invested in PDS Biotechnology in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 6

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

18% more funds holding

Funds holding: 39 → 46 (+7)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

31% less capital invested

Capital invested by funds: $158M → $109M (-$48.9M)

Holders
46
Holders Change
+7
Holders Change %
+17.95%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
18
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$2.02M
2
OM
Opaleye Management
Massachusetts
+$1.65M
3
Franklin Resources
Franklin Resources
California
+$883K
4
DCM
DAFNA Capital Management
California
+$618K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$547K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$15.8M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$231K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$197K
4
BFA
BlackRock Fund Advisors
California
-$106K
5
EAM
Eagle Asset Management
Florida
-$63.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$162K – – –
TC
27
TFS Capital
Pennsylvania
$121K +$119K +664 New
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$112K -$197K -1,100 -64%
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
$110K +$107K +600 New
WPC
30
White Pine Capital
Minnesota
$106K +$104K +581 New
TA
31
Teachers Advisors
New York
$77K – – –
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$65K +$63.5K +355 New
Citigroup
33
Citigroup
New York
$64K +$39K +218 +172%
NFA
34
Nationwide Fund Advisors
Ohio
$55K +$8.4K +47 +19%
AIG
35
American International Group
New York
$45K +$43.6K +244 New
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$38K +$36.1K +202 New
BA
37
BlackRock Advisors
Delaware
$27K – – –
SO
38
STRS Ohio
Ohio
$24K – – –
Wells Fargo
39
Wells Fargo
California
$22K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$22K +$12.5K +70 +140%
Deutsche Bank
41
Deutsche Bank
Germany
$11K -$7.51K -42 -40%
PCC
42
Park Circle Company
Maryland
$11K +$10.7K +60 New
MSFP
43
Mark Sheptoff Financial Planning
Connecticut
$9K +$8.94K +50 New
AIM
44
Advantage Investment Management
Iowa
$5K +$4.47K +25 New
BlackRock
45
BlackRock
New York
$1K +$1.07K +6 New
Geode Capital Management
46
Geode Capital Management
Massachusetts
$610 +$52.2K +292 +10%
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
– -$231K -923 Closed
UBS Group
48
UBS Group
Switzerland
– -$21K -86 Closed
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
– -$18.9K -76 Closed
TRCT
50
Tower Research Capital (TRC)
New York
– -$6K -26 Closed
1
2
3

PDSB Hedge Fund Activity: Q1 2016 in Review

46 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2016, worth a combined $109M — down 31% from $158M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PDSB positions and 6 closed out — a net gain of 7 holders — while 18 added to existing stakes and 6 trimmed.

The largest buyer was Acuta Capital Partners, adding an estimated $2.02M. The largest seller was Fidelity Investments, cutting an estimated $15.8M.

  • 46 institutional investors held PDS Biotechnology (PDSB) as of Q1 2016, up from 39 in Q4 2015.
  • Funds reported $109M of PDS Biotechnology stock for Q1 2016, down 31% quarter-over-quarter.
  • 13 funds opened new PDS Biotechnology positions in Q1 2016 and 6 closed out, a net change of +7 holders.
  • The largest PDS Biotechnology buyer in Q1 2016 was Acuta Capital Partners, an estimated $2.02M added.
  • The largest PDS Biotechnology seller in Q1 2016 was Fidelity Investments, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2016.